3Ruffolo RR Jr, Feuerstein GZ, Ohistein EH. Recent observation with β- adrenocepter blockade- Beneficial effcets in hypertension and heart failure[J]. Am J Hypertension, 1998, 11:9-14.
4Frishman WH. Drug therapy - carvedilol [ J ]. Drug therapy,1998, 339:1759-1762.
5Packer M, Bristow MR, Cohn IN, et al. Effect of Carvedilol on morbdity and mortality in chronic heart failure [ J ]. N Engl J Med, 1996, 334:1349-1355.
6Ruffolo RR Jr, Feuerstein GZ, OhisteinEH. Recent observation with β- adrenocepter blockade- Beneficial effcets in hypertension and heart failure[J ]. Am J Hypertension, 1998, 11: 9-14.
二级参考文献7
1Kalon KL,Joan LP, William BK. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol, 1993,22 (Suppl A):6A-13A.
2Hung YT, Cheug NT, Ip S. Epidemiology of heart failure in Hong Kong,1997. Hong Kong Med J, 2000,6:159-162.
3Packer M, Coats AJS, Fowler MB, et al. For the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effects of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001, 344:1651-1658.
4Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J, 2001, 22: 1527-1561.
5Hunt HA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the international society for heart and lung transplantation. Circulation, 2001, 104:2996-3007.
